Q3 2023 · 13F-HR
Atlas Venture Life Science Advisors, LLCholdings as filed
Filed 2023-11-13 · accession 0001104659-23-117225
$645.6M
Reported value
15
Positions
2023-09-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 254604101 | IRON | Disc Medicine, Inc. | $129.0M | 20.0% | 2,745,335 | Common | SOLE |
| 23954D109 | DAWNGBX | Day One Biopharmaceuticals, Inc. | $93.4M | 14.5% | 7,608,394 | Common | SOLE |
| 26818M108 | DYN | Dyne Therapeutics, Inc. | $88.6M | 13.7% | 9,885,449 | Common | SOLE |
| 501575104 | KYMR | Kymera Therapeutics, Inc. | $81.4M | 12.6% | 5,858,262 | Common | SOLE |
| 88427A107 | — | Third Harmonic Bio, Inc. | $69.7M | 10.8% | 10,907,859 | Common | SOLE |
| 76029N106 | REPL | Replimune Group, Inc. | $35.9M | 5.56% | 2,098,300 | Common | SOLE |
| 92673K108 | VIGL | Vigil Neuroscience, Inc. | $31.5M | 4.87% | 5,836,874 | Common | SOLE |
| 37148K100 | GBIOGBX | Generation Bio, Co. | $31.4M | 4.86% | 8,279,484 | Common | SOLE |
| 008064107 | — | Aerovate Therapeutics, Inc. | $27.7M | 4.29% | 2,039,249 | Common | SOLE |
| 45175G108 | — | Ikena Oncology, Inc. | $21.7M | 3.37% | 5,018,178 | Common | SOLE |
| 00973Y108 | AKRO | Akero Therapeutics, Inc. | $18.2M | 2.81% | 359,251 | Common | SOLE |
| 05455M100 | — | AvroBio, Inc. | $7.0M | 1.08% | 4,541,381 | Common | SOLE |
| 98422T100 | — | Xilio Therapeutics, Inc. | $5.8M | 0.90% | 2,759,344 | Common | SOLE |
| 252828108 | DNTH | Dianthus Therapeutics, Inc. | $3.2M | 0.50% | 236,979 | Common | SOLE |
| 84833T103 | SPRO | Spero Therapeutics, Inc. | $1.2M | 0.19% | 1,013,438 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.